GlycoMimetics Inc (NASDAQ:GLYC) shares traded 25.28% higher at $0.33 on Wall Street last session.
GLYC stock price is now -58.03% away from the 50-day moving average and -81.89% away from the 200-day moving average. The market capitalization of the company currently stands at $21.53M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $12, CapitalOne recently initiated with Overweight rating for GlycoMimetics Inc (NASDAQ: GLYC). On November 12, 2021, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $3 to quote $4, while ‘ROTH Capital’ rates the stock as ‘Buy’
In other news, Rock Edwin, Chief Medical Officer bought 115,000 shares of the company’s stock on Jun 21 ’24. The stock was bought for $30,716 at an average price of $0.27. Upon completion of the transaction, the Chief Medical Officer now directly owns 680,403 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 20 ’24, Chief Medical Officer Rock Edwin bought 190,000 shares of the business’s stock. A total of $48,108 was incurred on buying the stock at an average price of $0.25. This leaves the insider owning 565,403 shares of the company worth $0.19 million. A total of 6.07% of the company’s stock is owned by insiders.
During the past 12 months, GlycoMimetics Inc has had a low of $0.23 and a high of $3.53. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 6.28, and a quick ratio of 6.28. The fifty day moving average price for GLYC is $0.7966 and a two-hundred day moving average price translates $1.8449 for the stock.
The latest earnings results from GlycoMimetics Inc (NASDAQ: GLYC) was released for 2024-03-31. The net profit margin was -372770.97% and return on equity was -81.84% for GLYC.
